Figure 5
Figure 5. Treg cells expanded in RelB−/− BMCs are not responsible for the reduced effector T-cell expansion. Cohorts of irradiated WT and RelB−/− BMCs were transplanted with BM from PC61-treated Balb/c donors in combination with LN T cells from control or PC61-treated Balb/c donors. (A) Efficacy of donor Treg depletion was examined in LN cells from control mAb or PC61-treated Balb/c donors using 3-color flow cytometry with CD25-FITC, CD4-PE, and FoxpP3-Alexa647 mAbs (numbers represent proportion of LN cells in that quadrant). (B) Donor splenic CD4+ Treg (CD3+H2Dd-posCD4+FoxP3+) numbers and proportions within CD4+ compartment, and (C) effector CD4+ T cells (CD3+H2Dd-posCD4+FoxP3−) were quantitated, and (D) serum IFNγ and IL-5 levels were determined in allogeneic BMC transplant recipients 10 days after BMT. *P = .016, BMC transplant recipients: WT (■, n = 5) or RelB−/− (□, n = 4). Results represent mean ± SEM of individual animals.

Treg cells expanded in RelB−/− BMCs are not responsible for the reduced effector T-cell expansion. Cohorts of irradiated WT and RelB−/− BMCs were transplanted with BM from PC61-treated Balb/c donors in combination with LN T cells from control or PC61-treated Balb/c donors. (A) Efficacy of donor Treg depletion was examined in LN cells from control mAb or PC61-treated Balb/c donors using 3-color flow cytometry with CD25-FITC, CD4-PE, and FoxpP3-Alexa647 mAbs (numbers represent proportion of LN cells in that quadrant). (B) Donor splenic CD4+ Treg (CD3+H2Dd-posCD4+FoxP3+) numbers and proportions within CD4+ compartment, and (C) effector CD4+ T cells (CD3+H2Dd-posCD4+FoxP3) were quantitated, and (D) serum IFNγ and IL-5 levels were determined in allogeneic BMC transplant recipients 10 days after BMT. *P = .016, BMC transplant recipients: WT (■, n = 5) or RelB−/− (□, n = 4). Results represent mean ± SEM of individual animals.

Close Modal

or Create an Account

Close Modal
Close Modal